1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Proteasome Inhibitors (PI), Lenalidomide Not-Refractory, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM)
### Instruction:
Identify the study with the following condition. 
### Input:
1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Proteasome Inhibitors (PI), Lenalidomide Not-Refractory, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM) 
### Output:
Popular Name is ASPIRE, Study ID is NCT01080391